| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 11 |
| 1 | PREDNISONE | 10 |
| 2 | CYCLOPHOSPHAMIDE | 9 |
| 3 | CYCLOPHOSPHAMIDE FOR INJECTION | 9 |
| 4 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 9 |
| 5 | DOXORUBICIN | 9 |
| 6 | DEXAMETHASONE | 7 |
| 7 | DEXAMETHASONE 1.5 MG | 7 |
| 8 | CISPLATIN | 6 |
| 9 | CYTARABINE | 6 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NORETHINDRONE AND ETHINYL ESTRADIOL | 1 | 0.0009 |
| 1 | EPCORITAMAB-BYSP | 1 | 0.0007 |
| 2 | HYDROCORTISONE SODIUM SUCCINATE | 1 | 0.0003 |
| 3 | RITUXIMAB-ABBS | 1 | 0.0002 |
| 4 | BENDAMUSTINE HYDROCHLORIDE | 1 | 0.0001 |
| 5 | DOXORUBICIN | 9 | 0.0001 |
| 6 | CYTARABINE | 6 | 0.0001 |
| 7 | AXICABTAGENE CILOLEUCEL | 1 | 0.0001 |
| 8 | POLATUZUMAB VEDOTIN | 1 | 0.0001 |
| 9 | DIMENHYDRINATE | 1 | 0.0001 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 1 | 0.0002 |
| 1 | CD19-directed Chimeric Antigen Receptor [EPC] | 1 | 0.0001 |
| 2 | CD20-directed Cytolytic Antibody [EPC] | 13 | 0.0000 |
| 3 | Alkylating Drug [EPC] | 9 | 0.0000 |
| 4 | Topoisomerase Inhibitor [EPC] | 2 | 0.0000 |
| 5 | Nucleoside Metabolic Inhibitor [EPC] | 7 | 0.0000 |
| 6 | Platinum-based Drug [EPC] | 6 | 0.0000 |
| 7 | BCL-2 Inhibitor [EPC] | 1 | 0.0000 |
| 8 | Janus Kinase Inhibitor [EPC] | 2 | 0.0000 |
| 9 | Corticosteroid [EPC] | 11 | 0.0000 |